SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, vitamin B12b, and vitamin C with autologous hematopoietic stem cell infusion. A dose-escalation schedule is being employed for the vitamin C.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Rak trzustki lub rak piersi w zaawansowanym stadium IV
- •Oczekiwana długość życia co najmniej 6 miesięcy
- •Ogólny stan zdrowia oceniony na skali Karnofskiego'ego minimum 60%
- •Brak chemioterapii w ciągu 2 tygodni przed rozpoczęciem badania
- •Możliwość zmierzenia wielkości guza lub jego obecność bez możliwości pomiaru
- •Dla raka trzustki: gruczolakorak trzustki lub nowotwór acinarny
- •Dla raka piersi: adenocarcinoma piersi z ujemnym wynikiem HER2
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Massachusetts General Hospital
Boston, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Trial contact
General Oncology (study sponsor)
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.